Objective: To assess the efficacy and safety profile of docetaxel, as a single agent, in the treatment of elderly patients with advanced breast cancer. Methods: Twenty-eight patients, with a median ...
Investigators compared clinical outcomes with docetaxel rechallenge vs cabazitaxel in patients with mCRPC who did not experience disease progression during prior administration of docetaxel for mCRPC.
In this phase III, double-blind, placebo-controlled trial, patients with chemotherapy-naive, metastatic, unresectable uLMS were randomly assigned to gemcitabine-docetaxel plus bevacizumab or ...
Patients with prostate cancer who receive docetaxel with standard-of-care treatment may have a reduced risk of death and an improved prognosis, according to a recent study. Patients with prostate ...
The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically changed in recent years. However, aside from drug or hormonal therapies, other ...
Nubeqa plus androgen deprivation therapy and docetaxel to treat patients with metastatic hormone-sensitive prostate cancer lowered hospitalization rates but led to marginally longer lengths of stay ...
Experts project the diagnosis of over 300,000 prostate cancer cases in the United States in 2006, along with over 30,000 ...
Patients who received gemcitabine followed by docetaxel experienced a delay in the need for radical cystectomy. Sequential intravesical gemcitabine/docetaxel treatment for high-risk nonmuscle-invasive ...
Researchers have identified a receptor protein known as CHRM1 as a key player in prostate cancer cells' resistance to docetaxel, a commonly used chemotherapy drug to treat advanced cancer that has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results